Flightpath Biosciences, Inc.

DETROIT, MI / ACCESSWIRE / October 3, 2023 / Flightpath Biosciences, Inc. announced today that it has signed a landmark development agreement with The Forsyth Institute, a globally recognized leader in the fields of oral health research and clinical care. The development agreement contemplates a multi-indication and multi-year deal to develop new products and intellectual property, beginning with Flightpath's orally bioavailable, narrow-spectrum antibiotic, FP-100, for prevention and treatment of oral disease. Increasing evidence shows that oral bacteria play a significant role in systemic diseases like diabetes, Alzheimer's and heart disease. Leveraging Forsyth's intellectual property, animal models and deep clinical expertise and capabilities in oral health, the team will evaluate the drug's impact on early-stage periodontal disease, and associated inflammatory and neurodegenerative disorders. "We are thrilled to work with a partner that can help us unlock the value of our lead therapeutic candidate, FP-100, in this new area of high unmet need. It is abundantly clear that chronic oral infections and resultant inflammation play a key role in both oral disease and related systemic diseases. We're optimistic that this new collaboration will lead to a new wave of clinical options and approaches for patients with periodontal disease," said Matt Tindall, Flightpath Biosciences co-founder and CEO. Periodontal disease (PD) is a common chronic inflammatory disease that afflicts up to 50% of the adult population - more than 65 million Americans and hundreds of millions of patients globally. It is mainly the result of infections and inflammation of the gums and bone that surround and support the teeth. The annual direct costs related to the prevention and treatment of these persistent infections are over $3.5 billion in the U.S. alone. "FP-100 has demonstrated potential to eradicate both Treponemes and Fusobacterium, two critical pathogens in PD, without negatively impacting symbiont bacteria and with no evidence of biologically relevant toxicity in multiple animal species. Combining Flightpath's drug development expertise with Forsyth's tremendous oral health capabilities is an exciting moment for both parties and for patient care generally," said Kim Lewis, Flightpath Biosciences co-founder and Head of the Antimicrobial Discovery Center at Northeastern University. The research will be led by Alpdogan Kantarci, DDS, MSc, PhD, senior member of faculty at Forsyth, whose work examines the connections between PD and systemic disease. "Treponema and Fusobacterium are well-known causal pathogens in periodontal disease that are also associated with other serious systemic diseases. We believe the work planned between the teams has high potential to add new options to early therapeutic prevention, with implications beyond oral care." "We are excited to collaborate with Flightpath," said Wenyuan Shi, PhD, CEO, Forsyth Institute. "Focusing on the oral-systemic connections when developing therapeutics will allow us to make real progress in improving public health." Today, periodontal disease is frequently treated after diagnosis using an array of medical, mechanical and surgical approaches that range from education and control of risk factors to invasive, painful and expensive dental procedures. New methods of prevention and treatment are of growing importance, based on new learnings about the bacterial implications in systemic disease. There are relatively few safe and effective therapeutic options that can be used repeatedly in the later stages of progressing periodontal disease. A phase 1 clinical trial of FP-100 is expected to start in Q1 2024. Flightpath Biosciences, Inc. is a private, Series A-funded, near-clinical stage life sciences company headquartered in Detroit, Michigan. To date, the company's primary development focus has been on novel therapies to treat acute Lyme disease, which is advancing and remains ongoing. The company's lead drug candidate, FP-100, is a narrow-spectrum bactericidal compound with selective activity against spirochetal bacteria and Fusobacterium and limited impact on the gut microbiome. The Forsyth Institute, founded in 1910, is the world's leading independent research institution focused on oral health and its connection to overall wellness. Forsyth was founded as a pediatric dental hospital serving disadvantaged children in the Boston area. Today, the Institute is grounded in a three-pillared strategic plan focused on biological research, clinical care, and technological innovation. Forsyth carries out its original mission through a mobile public health dental program called ForsythKids. Contact Information Matt Tindall CEO info@flightpath.bio SOURCE: Flightpath Biosciences, Inc. View source version on accesswire.com:

NEW YORK, Aug. 2, 2023 /PRNewswire/ -- The human microbiome therapeutics market size is estimated to increase by USD 732.95 million from 2022 to 2027, at a CAGR of 30.11%, according to a recent market study by Technavio. This report also offers a 5-year historical (2017-2021) data projection of market size, segmentation, and region. Discover some insights on market size before buying the full report -Request a sample report Human Microbiome Therapeutics Market 2023-2027 – Vendor Scope Continue Reading Technavio has announced its latest market research report titled Global Human Microbiome Therapeutics Market The human microbiome therapeutics market report also offers information on the criticality of inputs, R&D, CAPEX, technology, and products of 15 companies listed below - 4D Pharma Plc, BiomX Inc., Eligo Bioscience, ENTEROME SA, Evelo Biosciences Inc., Evogene Ltd., Ferring BV, Finch Therapeutics Group Inc., Flightpath Biosciences, Johnson and Johnson Services Inc., MaaT Pharma, Microbiotica Ltd., OptiBiotix Health Plc, PureTech Health Plc, Second Genome Therapeutics, Seres Therapeutics Inc., Synlogic Inc., Takeda Pharmaceutical Co. Ltd., YSOPIA Bioscience, and Locus Biosciences Inc. Download a Sample Rep ort Chart & Data Table on 5-Year Historic (2017-2021) Market Size, Comparative Analysis of Segments, and Y-O-Y Growth of Human microbiome therapeutics market Human Microbiome Therapeutics Market 2023-2027: Segmentation The market is segmented by product (probiotics, prebiotics, medical foods, and prescription drugs), application (gastrointestinal disorders, infectious diseases, and others), and geography (North America, Europe, Asia, and the Rest of the World (ROW)) The market share of the probiotics segment is estimated to witness significant growth during the forecast period. Probiotics are living microbes that, when given in sufficient quantities, boost the host's health. Probiotics are bacteria and yeast that support a balanced microbial environment in human intestines. They are generally found in yogurt and other fermented foods. Additionally, they improve the immune system and shield lipids and proteins from oxidative damage. Hence, these factors are expected to drive segment growth during the forecast period. North America is estimated to contribute 41% to the growth of the global market during the forecast period. However, the region is expected to be slower than Europe and Asia. The market in the region is driven by factors such as significant investments in R & D for the development of novel therapeutic procedures and a high prevalence of gastrointestinal, metabolic, and immunological illnesses. Hence, these factors are expected to drive segment growth during the forecast period. To procure the data - Buy the report! Human Microbiome Therapeutics Market 2023-2027 – Market Dynamics Key Driver The growing prevalence of chronic diseases is a key factor driving market growth. These diseases also lead to the development of other serious diseases which include diabetes, hypertension, and obesity. Hypertension can also be caused by improper lifestyle choices and genetic factors. High blood pressure usually causes no symptoms. In addition, studies have shown that obese middle-aged men have a 50 to 60% higher risk of heart failure than nonobese middle-aged men. Hence, these factors are expected to drive market growth during the forecast period. Major Trends The increase in industry-academia collaboration for the development of novel therapeutics is a major trend in the market. To support the R&D of novel medicines for the treatment of diabetes, the major companies in the global pharmaceutical drugs industry are increasingly extending their assistance to academic institutions. Collaborations between businesses and academic institutions make it possible to combine the marketing knowledge of pharmaceutical companies with the scientific competence of academic organizations. Hence, this trend is expected to drive market growth during the forecast period. Significant Challenges The indiscriminate use of antibiotics is a significant challenge restricting market growth. In primary care, where viruses typically cause infections, overprescribing of antibiotics is a problem. The already overcrowded healthcare system incurs additional costs because of antibiotic resistance because it reduces both the number of medications that may be used for treatment and the long-term efficacy of the currently available drugs. But indiscriminate antibiotic use harms our body's natural flora and interferes with the effectiveness of microbial medicinal medicines. Hence, the above-mentioned factors are expected to restrict market growth during the forecast period. For Insights on the market dynamics & segmentations VIEW PDF SAMPLE! What are the key data covered in this Human Microbiome Therapeutics Market report? CAGR of the market during the forecast period Detailed information on factors that will drive the growth of the human microbiome therapeutics market between 2023 and 2027 Precise estimation of the size of the human microbiome therapeutics market and its contribution to the market with a focus on the parent market Accurate predictions about upcoming trends and changes in consumer behavior Growth of the human microbiome therapeutics market across North America, Europe, Asia, and Rest of the World (ROW) A thorough analysis of the market's competitive landscape and detailed information about companies Comprehensive analysis of factors that will challenge the growth of human microbiome therapeutics market companies. Gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform Related Reports The vertigo drugs market is estimated to grow by USD 551.42 million at a CAGR of 5.58% between 2022 and 2027. Furthermore, this report extensively covers market segmentation by type (vertigo, and central vertigo), distribution channel (offline and online), and geography (North America, Europe, Asia, and the Rest of the World (ROW)). Integration of digital health solutions in vertigo is a major trend in the market. The specialty pharmaceuticals market is estimated to grow by USD 331.12 billion at a CAGR of 12.59% between 2022 and 2027. Furthermore, this report extensively covers market segmentation by application (oncology, multiple sclerosis, inflammatory conditions, infectious diseases, and others), distribution channel (offline and online), and geography (North America, Europe, Asia, and the Rest of the World (ROW)). The increasing demand for R&D due to government healthcare expenditure is a key factor driving market growth during the forecast period. Table of Contents 1 Executive Summary 1.1 Market Overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Product Exhibit 06: Executive Summary – Chart on Market Segmentation by Application Exhibit 07: Executive Summary – Chart on Incremental Growth Exhibit 08: Executive Summary – Data Table on Incremental Growth Exhibit 09: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 10: Parent market Exhibit 11: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 12: Offerings of companies included in the market definition 3.2 Market segment analysis Exhibit 13: Market segments 3.3 Market size 2022 3.4 Market outlook: Forecast for 2022-2027 Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million) Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million) Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%) Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%) 4 Historic Market Size 4.1 Global human microbiome therapeutics market 2017 - 2021 Exhibit 18: Historic Market Size – Data Table on global human microbiome therapeutics market 2017 - 2021 ($ million) 4.2 Product Segment Analysis 2017 - 2021 Exhibit 19: Historic Market Size – Product Segment 2017 - 2021 ($ million) 4.3 Application Segment Analysis 2017 - 2021 Exhibit 20: Historic Market Size – Application Segment 2017 - 2021 ($ million) 4.4 Geography Segment Analysis 2017 - 2021 Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million) 4.5 Country Segment Analysis 2017 - 2021 Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million) 5 Five Forces Analysis 5.1 Five forces summary Exhibit 23: Five forces analysis - Comparison between 2022 and 2027 5.2 Bargaining power of buyers Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027 5.3 Bargaining power of suppliers Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027 5.4 Threat of new entrants Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027 5.5 Threat of substitutes Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027 5.6 Threat of rivalry Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027 5.7 Market condition Exhibit 29: Chart on Market condition - Five forces 2022 and 2027 6 Market Segmentation by Product 6.1 Market segments Exhibit 30: Chart on Product - Market share 2022-2027 (%) Exhibit 31: Data Table on Product - Market share 2022-2027 (%) 6.2 Comparison by Product Exhibit 32: Chart on Comparison by Product Exhibit 33: Data Table on Comparison by Product 6.3 Probiotics - Market size and forecast 2022-2027 Exhibit 34: Chart on Probiotics - Market size and forecast 2022-2027 ($ million) Exhibit 35: Data Table on Probiotics - Market size and forecast 2022-2027 ($ million) Exhibit 36: Chart on Probiotics - Year-over-year growth 2022-2027 (%) Exhibit 37: Data Table on Probiotics - Year-over-year growth 2022-2027 (%) 6.4 Prebiotics - Market size and forecast 2022-2027 Exhibit 38: Chart on Prebiotics - Market size and forecast 2022-2027 ($ million) Exhibit 39: Data Table on Prebiotics - Market size and forecast 2022-2027 ($ million) Exhibit 40: Chart on Prebiotics - Year-over-year growth 2022-2027 (%) Exhibit 41: Data Table on Prebiotics - Year-over-year growth 2022-2027 (%) 6.5 Medical foods - Market size and forecast 2022-2027 Exhibit 42: Chart on Medical foods - Market size and forecast 2022-2027 ($ million) Exhibit 43: Data Table on Medical foods - Market size and forecast 2022-2027 ($ million) Exhibit 44: Chart on Medical foods - Year-over-year growth 2022-2027 (%) Exhibit 45: Data Table on Medical foods - Year-over-year growth 2022-2027 (%) 6.6 Prescription drugs - Market size and forecast 2022-2027 Exhibit 46: Chart on Prescription drugs - Market size and forecast 2022-2027 ($ million) Exhibit 47: Data Table on Prescription drugs - Market size and forecast 2022-2027 ($ million) Exhibit 48: Chart on Prescription drugs - Year-over-year growth 2022-2027 (%) Exhibit 49: Data Table on Prescription drugs - Year-over-year growth 2022-2027 (%) 6.7 Market opportunity by Product Exhibit 50: Market opportunity by Product ($ million) Exhibit 51: Data Table on Market opportunity by Product ($ million) 7 Market Segmentation by Application 7.1 Market segments Exhibit 52: Chart on Application - Market share 2022-2027 (%) Exhibit 53: Data Table on Application - Market share 2022-2027 (%) 7.2 Comparison by Application Exhibit 54: Chart on Comparison by Application Exhibit 55: Data Table on Comparison by Application 7.3 Gastrointestinal disorders - Market size and forecast 2022-2027 Exhibit 56: Chart on Gastrointestinal disorders - Market size and forecast 2022-2027 ($ million) Exhibit 57: Data Table on Gastrointestinal disorders - Market size and forecast 2022-2027 ($ million) Exhibit 58: Chart on Gastrointestinal disorders - Year-over-year growth 2022-2027 (%) Exhibit 59: Data Table on Gastrointestinal disorders - Year-over-year growth 2022-2027 (%) 7.4 Infectious diseases - Market size and forecast 2022-2027 Exhibit 60: Chart on Infectious diseases - Market size and forecast 2022-2027 ($ million) Exhibit 61: Data Table on Infectious diseases - Market size and forecast 2022-2027 ($ million) Exhibit 62: Chart on Infectious diseases - Year-over-year growth 2022-2027 (%) Exhibit 63: Data Table on Infectious diseases - Year-over-year growth 2022-2027 (%) 7.5 Others - Market size and forecast 2022-2027 Exhibit 64: Chart on Others - Market size and forecast 2022-2027 ($ million) Exhibit 65: Data Table on Others - Market size and forecast 2022-2027 ($ million) Exhibit 66: Chart on Others - Year-over-year growth 2022-2027 (%) Exhibit 67: Data Table on Others - Year-over-year growth 2022-2027 (%) 7.6 Market opportunity by Application Exhibit 68: Market opportunity by Application ($ million) Exhibit 69: Data Table on Market opportunity by Application ($ million) 8 Customer Landscape 8.1 Customer landscape overview Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 9 Geographic Landscape 9.1 Geographic segmentation Exhibit 71: Chart on Market share by geography 2022-2027 (%) Exhibit 72: Data Table on Market share by geography 2022-2027 (%) 9.2 Geographic comparison Exhibit 73: Chart on Geographic comparison Exhibit 74: Data Table on Geographic comparison 9.3 North America - Market size and forecast 2022-2027 Exhibit 75: Chart on North America - Market size and forecast 2022-2027 ($ million) Exhibit 76: Data Table on North America - Market size and forecast 2022-2027 ($ million) Exhibit 77: Chart on North America - Year-over-year growth 2022-2027 (%) Exhibit 78: Data Table on North America - Year-over-year growth 2022-2027 (%) 9.4 Europe - Market size and forecast 2022-2027 Exhibit 79: Chart on Europe - Market size and forecast 2022-2027 ($ million) Exhibit 80: Data Table on Europe - Market size and forecast 2022-2027 ($ million) Exhibit 81: Chart on Europe - Year-over-year growth 2022-2027 (%) Exhibit 82: Data Table on Europe - Year-over-year growth 2022-2027 (%) 9.5 Asia - Market size and forecast 2022-2027 Exhibit 83: Chart on Asia - Market size and forecast 2022-2027 ($ million) Exhibit 84: Data Table on Asia - Market size and forecast 2022-2027 ($ million) Exhibit 85: Chart on Asia - Year-over-year growth 2022-2027 (%) Exhibit 86: Data Table on Asia - Year-over-year growth 2022-2027 (%) 9.6 Rest of World (ROW) - Market size and forecast 2022-2027 Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million) Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%) 9.7 US - Market size and forecast 2022-2027 Exhibit 91: Chart on US - Market size and forecast 2022-2027 ($ million) Exhibit 92: Data Table on US - Market size and forecast 2022-2027 ($ million) Exhibit 93: Chart on US - Year-over-year growth 2022-2027 (%) Exhibit 94: Data Table on US - Year-over-year growth 2022-2027 (%) 9.8 Germany - Market size and forecast 2022-2027 Exhibit 95: Chart on Germany - Market size and forecast 2022-2027 ($ million) Exhibit 96: Data Table on Germany - Market size and forecast 2022-2027 ($ million) Exhibit 97: Chart on Germany - Year-over-year growth 2022-2027 (%) Exhibit 98: Data Table on Germany - Year-over-year growth 2022-2027 (%) 9.9 France - Market size and forecast 2022-2027 Exhibit 99: Chart on France - Market size and forecast 2022-2027 ($ million) Exhibit 100: Data Table on France - Market size and forecast 2022-2027 ($ million) Exhibit 101: Chart on France - Year-over-year growth 2022-2027 (%) Exhibit 102: Data Table on France - Year-over-year growth 2022-2027 (%) 9.10 UK - Market size and forecast 2022-2027 Exhibit 103: Chart on UK - Market size and forecast 2022-2027 ($ million) Exhibit 104: Data Table on UK - Market size and forecast 2022-2027 ($ million) Exhibit 105: Chart on UK - Year-over-year growth 2022-2027 (%) Exhibit 106: Data Table on UK - Year-over-year growth 2022-2027 (%) 9.11 Japan - Market size and forecast 2022-2027 Exhibit 107: Chart on Japan - Market size and forecast 2022-2027 ($ million) Exhibit 108: Data Table on Japan - Market size and forecast 2022-2027 ($ million) Exhibit 109: Chart on Japan - Year-over-year growth 2022-2027 (%) Exhibit 110: Data Table on Japan - Year-over-year growth 2022-2027 (%) 9.12 Market opportunity by geography Exhibit 111: Market opportunity by geography ($ million) Exhibit 112: Data Tables on Market opportunity by geography ($ million) 10 Drivers, Challenges, and Trends 10.1 Market drivers 10.2 Market challenges 10.3 Impact of drivers and challenges Exhibit 113: Impact of drivers and challenges in 2022 and 2027 10.4 Market trends 11 Vendor Landscape 11.1 Overview 11.2 Vendor landscape Exhibit 114: Overview on Criticality of inputs and Factors of differentiation 11.3 Landscape disruption Exhibit 115: Overview on factors of disruption 11.4 Industry risks Exhibit 116: Impact of key risks on business 12 Vendor Analysis 12.1 Companies covered Exhibit 117: Companiescovered 12.2 Market positioning of companies Exhibit 118: Matrix on vendor position and classification 12.3 4D pharma Plc Exhibit 119: 4D pharma Plc - Overview Exhibit 120: 4D pharma Plc - Product / Service Exhibit 121: 4D pharma Plc - Key offerings 12.4 BiomX Inc. Exhibit 122: BiomX Inc. - Overview Exhibit 123: BiomX Inc. - Product / Service Exhibit 124: BiomX Inc. - Key offerings 12.5 Eligo Bioscience Exhibit 125: Eligo Bioscience - Overview Exhibit 126: Eligo Bioscience - Product / Service Exhibit 127: Eligo Bioscience - Key offerings 12.6 ENTEROME SA Exhibit 128: ENTEROME SA - Overview Exhibit 129: ENTEROME SA - Product / Service Exhibit 130: ENTEROME SA - Key offerings 12.7 Evelo Biosciences Inc. Exhibit 131: Evelo Biosciences Inc. - Overview Exhibit 132: Evelo Biosciences Inc. - Product / Service Exhibit 133: Evelo Biosciences Inc. - Key offerings 12.8 Evogene Ltd. Exhibit 134: Evogene Ltd. - Overview Exhibit 135: Evogene Ltd. - Business segments Exhibit 136: Evogene Ltd. - Key offerings Exhibit 137: Evogene Ltd. - Segment focus 12.9 Ferring BV Exhibit 138: Ferring BV - Overview Exhibit 139: Ferring BV - Product / Service Exhibit 140: Ferring BV - Key offerings 12.10 Finch Therapeutics Group Inc. Exhibit 141: Finch Therapeutics Group Inc. - Overview Exhibit 142: Finch Therapeutics Group Inc. - Product / Service Exhibit 143: Finch Therapeutics Group Inc. - Key offerings 12.11 Johnson and Johnson Services Inc. Exhibit 144: Johnson and Johnson Services Inc. - Overview Exhibit 145: Johnson and Johnson Services Inc. - Business segments Exhibit 146: Johnson and Johnson Services Inc. - Key news Exhibit 147: Johnson and Johnson Services Inc. - Key offerings Exhibit 148: Johnson and Johnson Services Inc. - Segment focus 12.12 OptiBiotix Health Plc Exhibit 149: OptiBiotix Health Plc - Overview Exhibit 150: OptiBiotix Health Plc - Product / Service Exhibit 151: OptiBiotix Health Plc - Key offerings 12.13 PureTech Health Plc Exhibit 152: PureTech Health Plc - Overview Exhibit 153: PureTech Health Plc - Business segments Exhibit 154: PureTech Health Plc - Key offerings Exhibit 155: PureTech Health Plc - Segment focus 12.14 Second Genome Therapeutics Exhibit 156: Second Genome Therapeutics - Overview Exhibit 157: Second Genome Therapeutics - Product / Service Exhibit 158: Second Genome Therapeutics - Key offerings 12.15 Seres Therapeutics Inc. Exhibit 159: Seres Therapeutics Inc. - Overview Exhibit 160: Seres Therapeutics Inc. - Product / Service Exhibit 161: Seres Therapeutics Inc. - Key offerings 12.16 Synlogic Inc. Exhibit 162: Synlogic Inc. - Overview Exhibit 163: Synlogic Inc. - Product / Service Exhibit 164: Synlogic Inc. - Key offerings 12.17 Takeda Pharmaceutical Co. Ltd. Exhibit 165: Takeda Pharmaceutical Co. Ltd. - Overview Exhibit 166: Takeda Pharmaceutical Co. Ltd. - Product / Service Exhibit 167: Takeda Pharmaceutical Co. Ltd. - Key news Exhibit 168: Takeda Pharmaceutical Co. Ltd. - Key offerings 13 Appendix 13.1 Scope of the report 13.2 Inclusions and exclusions checklist Exhibit 169: Inclusions checklist Exhibit 170: Exclusions checklist 13.3 Currency conversion rates for US$ Exhibit 171: Currency conversion rates for US$ 13.4 Research methodology Exhibit 172: Research methodology Exhibit 173: Validation techniques employed for market sizing Exhibit 174: Information sources 13.5 List of abbreviations Exhibit 175: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

CHICAGO, May 26, 2023 /PRNewswire/ -- The human microbiome industry is poised for exponential growth and transformative advancements in the near future. As our understanding of the intricate relationship between the trillions of microbes living in and on our bodies expands, so does the potential for harnessing the power of the microbiome to revolutionize healthcare. With cutting-edge research, technological innovations, and collaborative efforts across various disciplines, the industry is set to unlock novel therapeutic approaches, diagnostic tools, and personalized treatments. This will not only lead to breakthroughs in managing complex diseases such as gastrointestinal disorders, autoimmune conditions, and mental health disorders but also pave the way for precision medicine tailored to an individual's unique microbiome composition. The integration of microbiome research into clinical practice holds the promise of improved patient outcomes, reduced healthcare costs, and a shift towards preventive and personalized healthcare models. However, challenges in standardization, regulatory frameworks, and ethical considerations must be addressed to fully harness the potential of the human microbiome industry. As these barriers are overcome, the near future holds tremendous opportunities for transforming the way we approach human health and well-being through the dynamic and intricate world of the microbiome. Human Microbiome Market in terms of revenue was estimated to be worth $0.3 billion in 2023 and is poised to reach $1.7 billion by 2029, growing at a CAGR of 36.1% from 2023 to 2029 according to a new report by MarketsandMarkets™. Some of the prominent factors driving the growth of this market are advancements in technology, and the increasing awareness of personalized medicine are boosting the growth of the market. However, the regulatory challenges and limited understanding of microbial interactions can hamper the market growth. Download an Illustrative overview: Browse in-depth TOC on "Human Microbiome Market" 161 - Tables 34 - Figures 189 - Pages Human Microbiome Market Scope: Therapeutic segment accounted for the largest share of the human microbiome market Among the application, the human microbiome market is segmented into therapeutic, and diagnostics. In 2023, the therapeutic segment accounted for the largest share of the human microbiome market. Growth in this market segment can be attributed to increasing understanding of the crucial role that the microbiome plays in maintaining human health. It is also driven by increasing investment from pharmaceutical and biotechnology companies and the growing demand for personalized medicine. Diagnostics segment is the fastest-growing segment of the human microbiome market In 2023, the diagnostics segment accounted for the fastest-growing share of the application segment of human microbiome market. Market growth can largely be attributed to the advances in life science research on a vast number of diseases, and technological innovations in human genome mapping. The market is also driven by increasing investment from both the public and private sectors, rising prevalence of chronic diseases, regulatory support and guidelines, as well as the growing demand for personalized medicine. Asia Pacific: The fastest-growing region in the human microbiome market. The Asia Pacific human microbiome market is projected to grow at the highest CAGR during the forecast period, mainly due to increasing awareness of the importance of the microbiome in health and disease, the rising demand for personalized medicine, and advancements in sequencing technologies. The Asian market has also garnered significant attention from global players due to the increased focus on preventative healthcare and personalized medicine, driving the demand for human microbiomes. Request Sample Pages: Human Microbiome Market Dynamics: Drivers: Collaborative efforts between microbiome industry and academia for microbiome research Surging demand for personalized medicine Rising awareness about importance of human microbiome Restraints: Adverse impact of complex regulatory policies on commercialization of microbiomes Opportunities: Increased collaboration of key players and small innovative companies to work on new microbiome technologies Challenges: Slow patient adoption of microbiome-based therapies Complexities involved in development of microbiome therapies Key Market Players: The market for human microbiome is highly consolidated, with key players strategizing to capture the market. Prominent players in the human microbiome market are Seres Therapeutics, Inc. (US), Enterome (France), 4D pharma plc (UK), International Flavors & Fragrances Inc. (US), OptiBiotix Health Plc (UK), Ferring Pharmaceuticals (Switzerland), Synlogic, Inc. (US), Second Genome, Inc. (US), Vedanta Biosciences, Inc. (US), YSOPIA Bioscience (France), FlightPath Biosciences, Inc. (US), Finch Therapeutics Group, Inc. (US), AOBiome Therapeutics (US), BioGaia (Sweden), Quantbiome, Inc. (dba Ombre) (US), Viome Life Sciences, Inc. (US), BIOHM Health (US), DayTwo (US), Atlas Biomed (UK), Bione Ventures Private Limited (India), Luxia Scientific (France), Metabiomics (US), Sun Genomics (US), Seed Health (US), and Gnubiotics Sciences (Switzerland). Get 10% Free Customization on this Report: Recent Developments: In November 2021, Seres Therapeutics collaborated with Bacthera to manufacture SER-109. The company is a leading manufacturer for recurrent Clostridioides difficile infection (rCDI). As per the agreement, Bacthera is establishing a dedicated facility for commercial manufacturing in its new Microbiome Center of Excellence, a manufacturing site dedicated to the production of LBPs located on Lonza's Ibex campus in Visp, Switzerland. In June 2020, Enterome announced a new financing totaling $52.6million to progress the clinical development of its therapeutic pipeline, including the first clinical trials of EO2401, a novel 'OncoMimic' cancer immunotherapy. In July 2020, OptiBiotix Health PLC launched WellBiome, a revolutionary ingredient to support digestive, cardiovascular, and metabolic health. Human Microbiome Market Advantages: Potential for Personalized Medicine: The human microbiome is highly individualized, varying from person to person. This presents an opportunity for personalized medicine, where treatments and interventions can be tailored to an individual's specific microbiome composition. This personalized approach has the potential to improve treatment outcomes, minimize adverse effects, and enhance overall patient well-being. Expanded Therapeutic Options: The study of the human microbiome has unveiled its crucial role in maintaining health and preventing diseases. This understanding has led to the development of microbiome-based therapeutics, such as probiotics, prebiotics, and fecal microbiota transplantation, which offer new avenues for treating a range of conditions, including gastrointestinal disorders, autoimmune diseases, and infections. These therapies provide alternatives or complements to traditional drug-based approaches, expanding the therapeutic options available to patients. Diagnostic and Biomarker Potential: The human microbiome harbors a wealth of information that can serve as diagnostic markers for various diseases and conditions. By analyzing the composition and activity of the microbiome, researchers can identify microbial signatures associated with specific health states. This opens up possibilities for developing microbiome-based diagnostic tests and biomarkers that can aid in early disease detection, disease monitoring, and treatment response assessment. Advancements in Technology and Research: The field of human microbiome research is benefiting from rapid advancements in technology, including high-throughput sequencing, metagenomics, and bioinformatics. These tools enable comprehensive profiling of the microbiome, providing valuable insights into microbial diversity, functionality, and interactions with the host. As technology continues to evolve, our understanding of the human microbiome will deepen, leading to more targeted interventions and improved patient outcomes. Potential for Preventive Healthcare: The human microbiome has been linked to various aspects of health, including immune system development, metabolism, and mental well-being. By modulating the microbiome through interventions like dietary modifications, probiotics, or targeted therapeutics, it may be possible to prevent the onset or progression of certain diseases. This preventive approach has the potential to reduce healthcare costs and improve population health outcomes. The advantages offered by the human microbiome market make it an exciting and promising field in healthcare. As research and technological advancements continue, the potential for personalized treatments, novel diagnostics, and preventive healthcare approaches will drive further growth and innovation in this evolving industry. Human Microbiome market - Report Highlights: The value chain analysis, ecosystem analysis, and regulatory scenario are added in the market overview chapter. The new edition of the report provides updated market breakdown with detailed analysis on product, type, application and disease. The new edition of the report provides updated financial information till 2023 (depending on availability) for each listed company in a graphical representation. This would help in the easy analysis of the present status of profiled companies in terms of their financial strength, profitability, key revenue-generating region/country, and business segment focus in terms of the highest revenue-generating segment. Recent developments are helpful to understand market trends and growth strategies adopted by players in the market. Tracking product portfolios of prominent market players helps to analyze the major types in the human microbiome market. The new edition of the report provides an updated product portfolio of the companies profiled in the report. Market evaluation framework, market share analysis and competitive leadership mapping have been added in competitive landscape chapter of the report. The competitive leadership mapping has been updated considering recent developments in the company evaluation matrix. Related Reports: Microbiome Sequencing Services Market - Global Forecasts to 2028 Rapid Microbiology Testing Market - Global Forecasts to 2026 Laboratory Proficiency Testing Market - Global Forecasts to 2026 Clinical Microbiology Market - Global Forecasts to 2025 High Throughput Screening Market - Global Forecasts to 2025 About MarketsandMarkets™: MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients. The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry. To find out more, visit ™.com or follow us on Twitter, LinkedIn and Facebook. Contact: Mr. Aashish Mehra MarketsandMarkets™ INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: [email protected] Research Insight: Visit Our Website: Content Source: Logo: SOURCE MarketsandMarkets